Cargando…

Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients

AIM: To estimate the mean lifetime survival benefit, an essential component of health economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) for newly diagnosed glioblastoma patients. METHODS: We integrated EF-14 trial data with glioblastoma ep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guzauskas, Gregory F, Salzberg, Marc, Wang, Bruce CM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200060/ https://www.ncbi.nlm.nih.gov/pubmed/30124334 http://dx.doi.org/10.2217/cns-2018-0010

Ejemplares similares

Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma
por: Miller, Ryan, et al.
Publicado: (2022)

Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era
por: Carico, Christine, et al.
Publicado: (2012)

ES-2 Phase 3 TRIDENT Trial: Radiation and Temozolomide with or without Tumor Treating Fields in newly diagnosed glioblastoma
por: Nakada, Mitsutoshi
Publicado: (2020)

Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center
por: Chen, Chunjui, et al.
Publicado: (2022)

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
por: Vieito, Maria, et al.
Publicado: (2022)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI
por: Ly, K. Ina, et al.
Publicado: (2018)

Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study
por: Chen, Jie, et al.
Publicado: (2022)

Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
por: Kim, Byung Sup, et al.
Publicado: (2017)

NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma
por: Sim, Hao-Wen, et al.
Publicado: (2023)

Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
por: Nguyen, Ludovic T., et al.
Publicado: (2013)

Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme
por: Aherne, Noel J., et al.
Publicado: (2014)

Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial
por: Compter, Inge, et al.
Publicado: (2020)

A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
por: Attarian, Fahimeh, et al.
Publicado: (2021)

Updated systematic review and meta-analysis of extended adjuvant temozolomide in patients with newly diagnosed glioblastoma
por: Gupta, Tejpal, et al.
Publicado: (2023)

Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI
por: Ly, K. Ina, et al.
Publicado: (2019)

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
por: Wen, Patrick Yung, et al.
Publicado: (2020)

Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide
por: Tieu, Minh Thi, et al.
Publicado: (2015)

Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma
por: Zhu, Jay-Jiguang, et al.
Publicado: (2017)

Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean Patients
por: Joo, Jin-Deok, et al.
Publicado: (2012)

Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction
por: Mallick, Supriya, et al.
Publicado: (2015)

The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review
por: Alimohammadi, Ehsan, et al.
Publicado: (2020)

Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial
por: Saran, Frank, et al.
Publicado: (2021)

Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era
por: Paravati, Anthony J., et al.
Publicado: (2010)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab
por: Wen, Qiuting, et al.
Publicado: (2014)

Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis
por: Roh, Tae Hoon, et al.
Publicado: (2017)

Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies
por: Ohno, Makoto, et al.
Publicado: (2022)

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
por: Lim, Michael, et al.
Publicado: (2022)

Eighteen years’ experience with tumor treating fields in the treatment of newly diagnosed glioblastoma
por: Vymazal, Josef, et al.
Publicado: (2023)

JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma
por: Wakabayashi, Toshihiko, et al.
Publicado: (2018)

Prognosis of patients with newly diagnosed glioblastoma treated with molecularly targeted drugs combined with radiotherapy vs temozolomide monotherapy: A meta-analysis
por: Wang, Wen-Lei, et al.
Publicado: (2019)

Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis
por: Ballo, Matthew T., et al.
Publicado: (2023)

Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis: Erratum
Publicado: (2017)

A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma
por: Werlenius, Katja, et al.
Publicado: (2021)

Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review
por: Su, Jiahao, et al.
Publicado: (2016)

Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial
por: Martínez-García, María, et al.
Publicado: (2022)

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
por: Omuro, Antonio, et al.
Publicado: (2022)

Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study
por: She, Lei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u0h0gavdg8m075f7gu76ugqfn5